BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18214709)

  • 1. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
    Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
    Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study.
    Zhang XW; Li C; Ma XX; Zhao JX; An Y; Liu S; Li Y; Li ZG
    Clin Rheumatol; 2014 Jul; 33(7):939-45. PubMed ID: 24744152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
    Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
    Mok CC; Ho CT; Chan KW; Lau CS; Wong RW
    Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low- Versus High-dose Cyclophosphamide in Class III/IV Lupus Nephritis: A Retrospective Study from South Asia.
    Wijayaratne DR; Atukorala IG; Gunawardena NS; Wijesundara DA; Lanerolle RD
    Indian J Nephrol; 2023; 33(1):40-45. PubMed ID: 37197037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Kotb A; Wells GA
    Syst Rev; 2016 Sep; 5(1):155. PubMed ID: 27619512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide.
    Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A
    Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
    Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
    Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.